CTOs on the Move

Kallyope

www.kallyope.com

 
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology. Founded and headquartered in New York City, we are developing an industry-leading platform to harness the gut-brain axis. Our cross-disciplinary biotechnology team ...
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.kallyope.com
  • 430 East 29th Street 8th Floor
    New York, NY USA 10016
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Kallyope raised $66M on 02/22/2018
Kallyope raised $21M on 12/05/2018
Kallyope raised $112M on 03/05/2020

Similar Companies

Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

RCSB Protein Data Bank

The Protein Data Bank (PDB) was established as the 1st open access digital data resource in all of biology and medicine. It is today a leading global resource for experimental data central to scientific discovery.

Cardiome Pharma

Cardiome Pharma Corp. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avantra Biosciences FKA Decision Biomarkers

Avantra Biosciences FKA Decision Biomarkers, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IGM Biosciences

IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM and IgA antibodies that improve the treatment of cancer and other diseases since 2010.